Clinical Trial Detail

NCT ID NCT03805841
Title Phase 2 Study of Tarloxotinib in Patients With NSCLC Harboring EGFR Exon 20 Insertion or HER2-activating Mutations (RAIN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Rain Therapeutics Inc.
Indications

non-small cell lung carcinoma

Therapies

Tarloxotinib

Age Groups: adult senior

Additional content available in CKB BOOST